CN101137368B - 治疗糖尿病的罗氟司特 - Google Patents

治疗糖尿病的罗氟司特 Download PDF

Info

Publication number
CN101137368B
CN101137368B CN2006800072465A CN200680007246A CN101137368B CN 101137368 B CN101137368 B CN 101137368B CN 2006800072465 A CN2006800072465 A CN 2006800072465A CN 200680007246 A CN200680007246 A CN 200680007246A CN 101137368 B CN101137368 B CN 101137368B
Authority
CN
China
Prior art keywords
roflumilast
type
diabetes
pharmaceutically acceptable
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800072465A
Other languages
English (en)
Chinese (zh)
Other versions
CN101137368A (zh
Inventor
H·-P·克利
G·哈诺尔
D·豪瑟
B·施米特
D·不雷登布洛克
W·沃斯特
J·肯科维斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Nycomed Asset Management GmbH
Nycomed Germany Holding GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN101137368A publication Critical patent/CN101137368A/zh
Application granted granted Critical
Publication of CN101137368B publication Critical patent/CN101137368B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN2006800072465A 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特 Expired - Fee Related CN101137368B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101772.1 2005-03-08
EP05101772 2005-03-08
PCT/EP2006/060418 WO2006094933A1 (en) 2005-03-08 2006-03-03 Roflumilast for the treatment of diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100579547A Division CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Publications (2)

Publication Number Publication Date
CN101137368A CN101137368A (zh) 2008-03-05
CN101137368B true CN101137368B (zh) 2012-05-16

Family

ID=34938922

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800072465A Expired - Fee Related CN101137368B (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特
CN2012100579547A Pending CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100579547A Pending CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Country Status (15)

Country Link
US (2) US8017633B2 (cg-RX-API-DMAC7.html)
EP (1) EP1874308A1 (cg-RX-API-DMAC7.html)
JP (2) JP5091106B2 (cg-RX-API-DMAC7.html)
KR (1) KR101302838B1 (cg-RX-API-DMAC7.html)
CN (2) CN101137368B (cg-RX-API-DMAC7.html)
AU (1) AU2006222060B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609371A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599376C (cg-RX-API-DMAC7.html)
EA (1) EA015382B1 (cg-RX-API-DMAC7.html)
IL (2) IL185277A (cg-RX-API-DMAC7.html)
MX (1) MX2007010560A (cg-RX-API-DMAC7.html)
NO (1) NO20074943L (cg-RX-API-DMAC7.html)
NZ (1) NZ560269A (cg-RX-API-DMAC7.html)
WO (1) WO2006094933A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200706294B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068290A2 (en) 2002-02-11 2003-08-21 Antares Pharma, Inc. Intradermal injector
JP5216328B2 (ja) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド あらかじめ充填された針補助シリンジジェット式注射器
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
KR20090047546A (ko) * 2006-09-07 2009-05-12 니코메드 게엠베하 당뇨병을 위한 조합 치료
EP2990067B1 (en) 2008-03-10 2019-09-04 Antares Pharma, Inc. Injector safety device
CN101548972B (zh) * 2008-04-03 2012-10-17 万特制药(海南)有限公司 一种含有瑞格列奈的固体药物组合物
WO2010017285A2 (en) 2008-08-05 2010-02-11 Antares Pharma, Inc. Multiple dosage injector
EP4427737A3 (en) 2009-03-20 2024-11-20 Antares Pharma, Inc. Hazardous agent injection system
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
ES2970240T3 (es) 2012-03-06 2024-05-27 Antares Pharma Inc Jeringa precargada con característica de fuerza de ruptura
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
WO2013169804A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
CA2900672C (en) 2013-02-11 2018-03-27 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP3572108A1 (en) 2013-03-11 2019-11-27 Antares Pharma, Inc. Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
EP3165224A1 (en) * 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
JP2019519478A (ja) 2016-04-19 2019-07-11 ユレカ・ソシエテ・ア・レスポンサビリテ・リミテＵｒｅｋａ Ｓａｒｌ ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
GB202306663D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002191A1 (en) * 2000-05-25 2002-01-03 Richard Friesen Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
WO2004016596A1 (en) * 2002-08-19 2004-02-26 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
US20050049258A1 (en) * 2001-01-31 2005-03-03 Pfizer Inc Ether derivatives useful as inhibitors of PDE4 isozymes

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
DE69333688T2 (de) 1992-07-28 2005-11-03 Aventis Pharma Ltd., West Malling Inhibitoren von c-amp phosphodiesterase
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
EP0706513B1 (de) * 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
HUT76980A (hu) 1994-08-29 1998-01-28 Yamanouchi Pharmaceutical Co. Ltd. Új naftiridinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
PT882021E (pt) 1996-01-31 2003-07-31 Altana Pharma Ag Novas fenantridinas
DE19617864A1 (de) 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EP1012188B1 (de) 1997-09-12 2004-08-18 Pharis Biotec GmbH Zusammensetzung zur therapie von diabetes mellitus und fettsucht
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DK1147103T3 (da) 1999-01-15 2005-08-29 Altana Pharma Ag Phenanthridin-N-oxider med PDE-IV-inhiberende aktivitet
BR0007527B1 (pt) 1999-01-15 2011-12-27 fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001035979A2 (en) 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
DE60008917T2 (de) 1999-12-08 2005-03-10 Grelan Pharmaceutical Co., Ltd., Hamura Neue 1,8-naphtyridin-2(1h)-on-derivate
US6423714B2 (en) 2000-03-13 2002-07-23 Ortho Mcneil-Pharmaceutical, Inc.. Cyclohexene derivatives useful as antagonists of the motilin receptor
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2002014280A1 (en) 2000-08-11 2002-02-21 Ono Pharmaceutical Co., Ltd. Piperidine derivatives and drugs containing these derivatives as the active ingredient
CN1446084A (zh) 2000-08-11 2003-10-01 辉瑞大药厂 胰岛素抗性综合症的治疗
NZ527081A (en) 2001-01-22 2006-03-31 Memory Pharm Corp Aniline derivatives useful as phosphodiesterase 4 inhibitors
MXPA03006886A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidazolilico utiles como inhibidores de las isozimas pde4.
JP4301812B2 (ja) 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
DK1511481T3 (da) * 2002-05-28 2011-01-24 Nycomed Gmbh Ophthalmologisk anvendelse af roflumilast til behandling af øjensygdomme
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
CN1791429A (zh) * 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
WO2005020926A2 (en) * 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
CA2542277A1 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
CN101027560A (zh) 2004-04-13 2007-08-29 艾尼纳制药公司 用于治疗高血糖症和相关病症的人类g蛋白偶合受体及其调节物
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002191A1 (en) * 2000-05-25 2002-01-03 Richard Friesen Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
US20050049258A1 (en) * 2001-01-31 2005-03-03 Pfizer Inc Ether derivatives useful as inhibitors of PDE4 isozymes
WO2004016596A1 (en) * 2002-08-19 2004-02-26 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
US 20020002191 A1,说明书第0015和0049段.

Also Published As

Publication number Publication date
JP2008532974A (ja) 2008-08-21
IL221006A0 (en) 2012-08-30
US8017633B2 (en) 2011-09-13
CN101137368A (zh) 2008-03-05
HK1116077A1 (en) 2008-12-19
CA2599376C (en) 2014-05-13
JP2012188448A (ja) 2012-10-04
CA2599376A1 (en) 2006-09-14
US8541456B2 (en) 2013-09-24
IL185277A0 (en) 2008-02-09
WO2006094933A1 (en) 2006-09-14
IL185277A (en) 2013-08-29
US20080214625A1 (en) 2008-09-04
US20110269750A1 (en) 2011-11-03
EA200701845A1 (ru) 2008-02-28
KR20070111539A (ko) 2007-11-21
NZ560269A (en) 2010-12-24
EP1874308A1 (en) 2008-01-09
ZA200706294B (en) 2008-09-25
AU2006222060B2 (en) 2011-09-01
EA015382B1 (ru) 2011-08-30
BRPI0609371A2 (pt) 2010-03-30
AU2006222060A1 (en) 2006-09-14
NO20074943L (no) 2007-10-01
CN102600144A (zh) 2012-07-25
JP5091106B2 (ja) 2012-12-05
JP5611275B2 (ja) 2014-10-22
KR101302838B1 (ko) 2013-09-03
MX2007010560A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
CN101137368B (zh) 治疗糖尿病的罗氟司特
CN101511364B (zh) 用于糖尿病的治疗组合
CN1960735B (zh) 药物组合在治疗胰岛素抗性中的应用
AU2025201814A1 (en) Therapeutic uses of GLP1R agonists
KR20150013838A (ko) 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
KR101951220B1 (ko) 조합 als 치료법
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
US20210401880A1 (en) Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient
WO2006094942A1 (en) Roflumilast for the treatment of diabetes mellitus
HK1116077B (en) Roflumilast for the treatment of diabetes mellitus
HK1171663A (en) Roflumilast for treatment of diabeties mellitus
AU2011253752A1 (en) Roflumilast for the treatment of diabetes mellitus
HK1098700B (en) Use of drug combinations for treating insulin resistance

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116077

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1116077

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

ASS Succession or assignment of patent right

Owner name: NYCOMED GERMANY HOLDING GMBH

Free format text: FORMER OWNER: NYCOMED ASSET MANAGEMENT GMBH

Effective date: 20150619

Owner name: NYCOMED ASSET MANAGEMENT GMBH

Free format text: FORMER OWNER: TAKEDA GMBH

Effective date: 20150619

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED GERMANY HOLDING GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed Germany holding LLC

TR01 Transfer of patent right

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed Germany holding LLC

Address before: Konstanz

Patentee before: Nycomed asset management LLC

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed asset management LLC

Address before: Konstanz

Patentee before: TAKEDA GmbH

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120516

Termination date: 20160303

CF01 Termination of patent right due to non-payment of annual fee